1. Home
  2. BETR vs ADCT Comparison

BETR vs ADCT Comparison

Compare BETR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

HOLD

Current Price

$38.30

Market Cap

538.7M

Sector

Finance

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.37

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BETR
ADCT
Founded
2014
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
538.7M
484.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BETR
ADCT
Price
$38.30
$4.37
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$40.00
$7.75
AVG Volume (30 Days)
517.9K
630.5K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
$54.06
N/A
Revenue Next Year
$66.68
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$10.81
$1.14
52 Week High
$94.06
$4.98

Technical Indicators

Market Signals
Indicator
BETR
ADCT
Relative Strength Index (RSI) 55.60 61.38
Support Level $26.89 $3.28
Resistance Level $41.23 $4.32
Average True Range (ATR) 3.54 0.23
MACD 0.09 0.04
Stochastic Oscillator 49.90 100.00

Price Performance

Historical Comparison
BETR
ADCT

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: